In chemistry, an enantiomer (/ -, - -/, ə-NAN-tee-ə-mər; from Greek ἐνάντιος (enántios), meaning 'opposite', and μέρος (méros), meaning 'part') (also named optical isomer, antipode, or optical antipode) is one of two stereoisomers that are mirror images of each other that are non-superposable (not identical), much as one's left and right hands are mirror images of each other that cannot appear identical simply by reorientation. A single chiral atom or similar structural feature in a compound causes that compound to have two possible structures which are non-superposable, each a mirror image of the other. Each member of the pair is termed an enantiomorph (enantio = opposite; morph = form); the structural property is termed enantiomerism. The presence of multiple chiral features in a given compound increases the number of geometric forms possible, though there may still be some perfect-mirror-image pairs.
When present in a symmetric environment, enantiomers have identical chemical and physical properties except for their ability to rotate plane-polarized light (+/−) by equal amounts but in opposite directions (although the polarized light can be considered an asymmetric medium). Such compounds are therefore described as optically active, with specific terms for each enantiomer based on the direction: a dextrorotatory compound rotates light a clockwise (+) direction whereas a levorotatory compound rotates light in a counter-clockwise (–) direction. A mixture of equal number of both enantiomers is called a racemic mixture or a racemate. In a racemic mixture, the amount of positive rotation is exactly counteracted by the equal amount of negative rotation, so the net rotation is zero (the mixture is not optically active). For all intents and purposes, pairs of enantiomers have the same Gibbs free energy. However, theoretical physics predicts that due to parity violation of the weak nuclear force (the only force in nature that can "tell left from right"), there is actually a minute difference in energy between enantiomers (on the order of 10−12 eV or 10−10 kJ/mol or less) due to the weak neutral current mechanism. This difference in energy is far smaller than energy changes caused by even a trivial change in molecular conformation and far too small to measure by current technology, and is therefore chemically inconsequential.
Enantiomer members often have different chemical reactions with other enantiomer substances. Since many biological molecules are enantiomers, there is sometimes a marked difference in the effects of two enantiomers on biological organisms. In drugs, for example, often only one of a drug's enantiomers is responsible for the desired physiological effects, while the other enantiomer is less active, inactive, or sometimes even productive of adverse effects. Owing to this discovery, drugs composed of only one enantiomer ("enantiopure") can be developed to make the drug work better and sometimes eliminate some side effects. An example is eszopiclone (Lunesta), which is just a single enantiomer of an older racemic drug called zopiclone. One enantiomer is responsible for all the desired effects, while the other enantiomer seems to be inactive, so the dose of eszopiclone is half that of zopiclone.
In chemical synthesis of enantiomeric substances, non-enantiomeric precursors inevitably produce racemic mixtures. In the absence of an effective enantiomeric environment (precursor, chiral catalyst, or kinetic resolution), separation of a racemic mixture into its enantiomeric components is impossible, although certain racemic mixtures spontaneously crystallize in the form of a racemic conglomerate, in which crystals of the enantiomers are physically segregated and may be separated mechanically (e.g., the enantiomers of tartaric acid, whose crystallized enantiomers were separated with tweezers by Pasteur). However, most racemates will crystallize in crystals containing both enantiomers in a 1:1 ratio, arranged in a regular lattice.
The R/S system is an important nomenclature system used to denote distinct enantiomers. Another system is based on prefix notation for optical activity: (+)- and (−)- or d- and l-. The Latin words for left are laevus and sinister, and the word for right is dexter (or rectus in the sense of correct or virtuous). The English word right is a cognate of rectus. This is the origin of the L/D and S/R notations, and the employment of prefixes levo- and dextro- in common names.
The prefix ent- to a chemical name can be used to refer to the chemical that is the enantiomer of the one indicated by the name.
Criterion of enantiomerism
An asymmetric carbon atom is one which has bonds with four different atoms or groups, so that these bonds can be arranged in two different ways which are not superposable. Most compounds that contain one or more asymmetric carbon (or other element with a tetrahedral geometry) atoms show enantiomerism, but this is not always true. Compounds that contain two or more asymmetric carbon atoms but have a plane of symmetry with respect to the whole molecule are known as meso compounds. A meso compound does not have a mirror image stereoisomer because it is its own mirror image (i.e., it and its mirror image are the same molecule). For instance, meso tartaric acid (shown on the right) has two asymmetric carbon atoms, but it does not exhibit enantiomerism because each of the two halves of the molecule is equal and opposite to the other and thus is superposable on its geometric mirror image. Conversely, there exist forms of chirality that do not require individual asymmetric atoms. In fact, there are four distinct types of chirality: central, axial, planar, and helical chirality. Having an enantiomer by virtue of an asymmetric carbon atom represents the most common type of central chirality. The other three types of chirality do not involve asymmetric carbon atoms, and even central chirality does not require the center of chirality to be located at a carbon or any other atom. Consequently, while the presence of an asymmetric carbon atom is a convenient characteristic to look for when determining whether a molecule will have an enantiomer, it is neither sufficient nor necessary as a criterion.
As a rigorous criterion, a molecule is chiral, and will therefore possess an enantiomer, if and only if it belongs to one of the chiral point groups: Cn, Dn, T, O, and I. However, as a caveat, enantiomers are not necessarily isolable if there is an accessible pathway for racemization at a given temperature and timescale. For example, amines with three distinct substituents are chiral, but with the exception of only a few atypical cases (e.g. substituted N-chloroaziridines), they rapidly planarize and invert ("umbrella inversion") at room temperature, leading to racemization. If the racemization is fast enough, the molecule can often be treated as an achiral, averaged structure.
An example of such an enantiomer is the sedative thalidomide, which was sold in a number of countries around the world from 1957 until 1961. It was withdrawn from the market when it was found to cause birth defects. One enantiomer caused the desirable sedative effects, while the other, unavoidably present in equal quantities, caused birth defects.
Another example is the antidepressant drugs escitalopram and citalopram. Citalopram is a racemate [1:1 mixture of (S)-citalopram and (R)-citalopram]; escitalopram [(S)-citalopram] is a pure enantiomer. The dosages for escitalopram are typically 1/2 of those for citalopram.
There are two main strategies for the preparation of enantiopure compounds. The first is known as chiral resolution. This method involves preparing the compound in racemic form, and separating it into its isomers. In his pioneering work, Louis Pasteur was able to isolate the isomers of tartaric acid because they crystallize from solution as crystals each with a different symmetry. A less common method is by enantiomer self-disproportionation.
The second strategy is asymmetric synthesis: the use of various techniques to prepare the desired compound in high enantiomeric excess. Techniques encompassed include the use of chiral starting materials (chiral pool synthesis), the use of chiral auxiliaries and chiral catalysts, and the application of asymmetric induction. The use of enzymes (biocatalysis) may also produce the desired compound.
Enantioconvergent synthesis is the synthesis of one enantiomer from a racemic precursor molecule utilizing both enantiomers. Thus, the two enantiomers of the reactant produce a single enantiomer of product.
Advances in industrial chemical processes have made it economic for pharmaceutical manufacturers to take drugs that were originally marketed as a racemic mixture and market the individual enantiomers. In some cases, the enantiomers have genuinely different effects. In other cases, there may be no clinical benefit to the patient. In some jurisdictions, single-enantiomer drugs are separately patentable from the racemic mixture. It is possible that only one of the enantiomers is active. Or, it may be that both are active, in which case separating the mixture has no objective benefits, but extends the drug's patentability.
- "enantiomer - definition of enantiomer in English from the Oxford dictionary". OxfordDictionaries.com. Retrieved 2016-01-20.
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "optical isomers". doi:10.1351/goldbook.O04308
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "antipode". doi:10.1351/goldbook.A00403
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "optical antipodes". doi:10.1351/goldbook.O04304
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "enantiomer". doi:10.1351/goldbook.E02069
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "enantiomorph". doi:10.1351/goldbook.E02079
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "enantiomerically pure (enantiopure)". doi:10.1351/goldbook.E02072
- IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "racemate". doi:10.1351/goldbook.R05025
- 1921-2008., Eliel, Ernest L. (Ernest Ludwig) (1994). Stereochemistry of organic compounds. Wilen, Samuel H., Mander, Lewis N. New York: Wiley. ISBN 0471016705. OCLC 27642721.CS1 maint: numeric names: authors list (link)
- Albert, Guijarro (2008). The origin of chirality in the molecules of life: a revision from awareness to the current theories and perspectives of this unsolved problem. Yus, Miguel. Cambridge, UK: Royal Society of Chemistry. ISBN 9781847558756. OCLC 319518566.
- In the sense used by particle physicists (see ref. 6), the "true" enantiomer of a molecule, which has exactly the same mass-energy content as the original molecule, is a mirror-image, but also built from antimatter (antiprotons, antineutrons, and positrons). Nevertheless, in this article, "enantiomer" will be used in the chemical sense and continue to refer to a nonidentical, mirror-image isomeric compound, consisting of ordinary matter elementary particles, in particular.
- "P-101.8.1 Inversion of configuration", IUPAC Provisional Recommendations—Preferred IUPAC Names (PDF), p. 48
- Knoche, B; Blaschke, G (1994). "Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography". Journal of Chromatography A. Elsevier. 666 (1–2): 235–240. doi:10.1016/0021-9673(94)80385-4.
- Voet, Donald; Voet, Judith G.; Pratt, Charlotte W. (2006). Fundamentals of Biochemistry. p. 89. ISBN 0-471-21495-7.
- G. Smith; C. H. L. Kennard; A. H. White; P. G. Hodgson (April 1980). "(±)-2-(4-Chloro-2-methylphenoxy)propionic acid (mecoprop)". Acta Crystallogr. B. 36 (4): 992–994. doi:10.1107/S0567740880005134.
- "European Medicines Agency - - Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone)". www.ema.europa.eu.
- Merrill Goozner (2004). The $800 Million Pill: The Truth Behind the Cost of New Drugs (excerpt). University of California Press. ISBN 0-520-23945-8.
- G.S. Coumbarides, M. Dingjan, J. Eames, A. Flinn, J. Northen and Y. Yohannes, Tetrahedron Lett. 46 (2005), p. 2897er